The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background Polycystic ovary syndrome (PCOS) is the most common endocrine condition in women, impacting several aspects of a woman's life, including reproductive, mental, cardiovascular, and metabolic health. Antidiabetic drugs may have beneficial effects on the endocrine and metabolic states in women with PCOS.Objective This study aimed to compare the effects of oral antidiabetic drugs on reproductive hormones, metabolic and anthropometric markers, and menstrual frequency, in patients with PCOS using network meta-analysis.Methods PubMed, EMBASE, and CENTRAL were searched for studies published up to May 31, 2021. Randomised clinical trials enrolling participants with PCOS were included, for which sodium-glucose cotransporter 2 (SGLT-2) inhibitors, metformin (Met), dipeptidyl peptidase 4 (DPP-4) inhibitors, alpha-glucosidase inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), and thiazolidinediones (TZDs) (alone or in combination) were compared with either each other, placebo, or no treatment. A network meta-analysis using a Bayesian approach was performed. The outcomes included changes in endocrine outcomes, metabolic results, menstrual frequency, and anthropometric findings. All research was conducted according to a protocol registered in the PROSPERO database (CRD42021248314).Results In total, we retrieved 3383 studies, of which 47 articles enrolling 2626 participants were included for the network meta-analysis. In comparison to the control groups, Met (MD - 0.41, 95% CI - 0.73 to - 0.09) was more beneficial in reducing serum total testosterone, and GLP-1RAs+Met (MD - 5.44, 95% CI - 10.06 to - 0.89) reduced free androgen index (FAI) more effectively. Thiazolidinediones (MD 9.33, 95% CI 0.15 to 17.99) had a greater effect on sex hormone-binding globulin (SHBG) than Met. For decreasing androstenedione, Met (MD - 1.87, 95% CI - 2.73 to - 1.01), DPP-4 inhibitors (MD - 2.64, 95% CI - 4.77 to - 0.49), GLP-1RAs (MD - 3.06, 95% CI - 5.53 to - 0.62), and GLP-1RAs+Met (MD - 2.97, 95% CI - 5.85 to - 0.09) were more effective than TZDs. The confidence in evidence was often low or very low.Conclusions In this network meta-analysis, GLP-1 receptor agonists in combination with metformin appear to be preferable for improving hyperandrogenaemia. Metformin and TZDs offer the added benefit of improving fasting blood glucose (FBG) and low-density lipoprotein-cholesterol (LDL-C) when compared to the control groups. Metformin combined with GLP-1 receptor agonists or TZDs could be associated with a beneficial effect on menstrual recovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the results of a very recent systematic review and network meta-analysis aimed to compare the effects of oral antidiabetic drugs in endocrine and metabolic profiles in patients with PCOS confirmed that metformin was more beneficial in reducing serum total testosterone, whereas GLP-1RA + metformin reduced FAI more effectively [24].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [24]
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092 · cited 1×
“org) [11] were used to automatically eliminate duplicate literature.”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“This network meta-analysis has been reported following the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA-NMA) [10].”
MethodCumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218 · cited 2×
“This network meta-analysis has been reported following the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA-NMA) [10].”
MethodConsistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098 · cited 1×
“A design-by-treatment test [18] was used to check the assumption of consistency across the entire analytical network.”
MethodProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 1×
“There is ample evidence that insulin resistance (44–70%) exists in both obese and lean women with PCOS, which is connected to its aetiology [2, 3].”
BackgroundCINeMA: an approach for assessing confidence in the results of a network meta-analysis
Nikolakopoulou, A., Higgins, J. P. T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., & Salanti, G. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003082 · Cited by 1,935 · cited 1×
“Furthermore, the evidence was assessed using the CINeMA system (Confidence in Network MetaAnalysis), an adaption of the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) approach for network meta-analysis [16].”
MethodHuhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753 · cited 1×
“3 software, with each domain judged as low risk, high risk or unclear risk [15].”
Method
Cited by
Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02084-6 · Cited by 29
Brand, K. M. G., Gottwald‐Hostalek, U., & Andag‐Silva, A. (2025) · Women s Health · doi:10.1177/17455057241311759 · Cited by 38
“44 The latter analysis found no significant differences between metformin and clomifene citrate, or between clomifene citrate plus metformin and metformin (Figure 3).”
InfluentialGLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence
Varughese, M. S., O’Mahony, F., & Varadhan, L. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100298 · Cited by 32
Zhou, J., Wei, Z., Lai, W., Liu, M., & Wu, X. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16354 · Cited by 29
“11,12 These inhibitors also positively affect hormonal parameters, including decreased free androgens and increased sex hormone-binding globulin levels.”
Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome
Lempesis, I. G., Apple, S. J., Duarte, G., Palaiodimos, L., Kalaitzopoulos, D. R., Dalamaga, Μ., & Kokkinidis, D. G. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3682 · Cited by 25
“tive hormones, and metabolic and anthropometric markers in patients with PCOS.(140) In this study, SGLT‐2i showed the most”
Background
Metadata
- Authors
- Yang, S., Zhao, L., He, W., & Mi, Y.
- Affiliations
- Liaoning Provincial People's Hospital (CN)
- China Medical University (CN)
- Corresponding author
- Yang, Shuo
- Venue
- Drugs
- Published
- 2022-09
- Volume
- 82
- Issue
- 14
- Pages
- 1469-1480
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W4296967408
- Cited by
- 33
- References
- 30
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 7 · 2023: 4
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, oral antidiabetic drugs, metformin, SGLT2 inhibitors, DPP-4 inhibitors, alpha-glucosidase inhibitors, GLP-1 receptor agonists, thiazolidinediones, testosterone, free androgen index, sex hormone-binding globulin, androstenedione, menstrual frequency, ovulation, insulin resistance
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Network Meta-Analysis, Network Meta-Analysis as Topic, Glucagon-Like Peptide-1 Receptor Agonists, Bayes Theorem, Female, Humans, Hypoglycemic Agents, Metformin, Polycystic Ovary Syndrome, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis. https://app.cochat.ai/papers/10.1007/s40265-022-01779-z
- The paper
- Yang, S., Zhao, L., He, W., & Mi, Y. (2022). The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis. Drugs. https://doi.org/10.1007/s40265-022-01779-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.